Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Alley

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Clinical Pharmacology|September 29, 2020
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy SubjectsAriel R Topletz-Erickson, Anthony J Lee, JoAl G Mayor, et al.
Bioconjugate Chemistry|September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfidesMichael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Molecular Cancer Therapeutics|September 16, 2008
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic indexCharlotte F McDonagh, Kristine M Kim, Eileen Turcott, et al.
Bioconjugate Chemistry|January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Molecular Cancer Therapeutics|August 30, 2008
Anti-CD30 diabody-drug conjugates with potent antitumor activityKristine M Kim, Charlotte F McDonagh, Lori Westendorf, et al.
The Journal of Clinical Investigation|July 15, 2025
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumorsFernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira, et al.
Blood|January 17, 2009
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomasHans-Peter Gerber, May Kung-Sutherland, Ivan Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylationNicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Bioanalysis|December 3, 2015
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies)Brad Ackermann, Hendrik Neubert, Nicola Hughes, et al.
Bioanalysis|December 24, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity)Lauren Stevenson, Lakshmi Amaravadi, Heather Myler, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Clinical Pharmacology|September 29, 2020
Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy SubjectsAriel R Topletz-Erickson, Anthony J Lee, JoAl G Mayor, et al.
Bioconjugate Chemistry|September 22, 2005
Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfidesMichael M C Sun, Kevin S Beam, Charles G Cerveny, et al.
Molecular Cancer Therapeutics|September 16, 2008
Engineered anti-CD70 antibody-drug conjugate with increased therapeutic indexCharlotte F McDonagh, Kristine M Kim, Eileen Turcott, et al.
Bioconjugate Chemistry|January 19, 2006
Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicitySvetlana O Doronina, Brian A Mendelsohn, Tim D Bovee, et al.
Molecular Cancer Therapeutics|August 30, 2008
Anti-CD30 diabody-drug conjugates with potent antitumor activityKristine M Kim, Charlotte F McDonagh, Lori Westendorf, et al.
The Journal of Clinical Investigation|July 15, 2025
First-generation and preclinical evaluation of an EphA5-targeted antibody-drug conjugate in solid tumorsFernanda I Staquicini, Fenny Hf Tang, Vanessa de Oliveira, et al.
Blood|January 17, 2009
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomasHans-Peter Gerber, May Kung-Sutherland, Ivan Stone, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 16, 2013
Development of orally active inhibitors of protein and cellular fucosylationNicole M Okeley, Stephen C Alley, Martha E Anderson, et al.
Bioanalysis|December 3, 2015
2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 2 - hybrid LBA/LCMS and input from regulatory agencies)Brad Ackermann, Hendrik Neubert, Nicola Hughes, et al.
Bioanalysis|December 24, 2014
2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 - LBA and immunogenicity)Lauren Stevenson, Lakshmi Amaravadi, Heather Myler, et al.
Pageof 4